5B3, 5B6, 5C2, 6D8, 6E10, 7F11, 7G11, 9E3, 10C1, [10D8, 10F6, 11G5,] 13H8, 14F12, and 15G7, which is covalently bound to a detectable marker or a water insoluble matrix.

C 1

21. A composition suitable for administration to a patient consisting of a monoclonal antibody selected from the group consisting of monoclonal antibodies 5B3, 5B6, 5C2, 6D8, 6E10, 7F11, 7G11, 9E3, 10C1, [10D8, 10F6, 11G5,] 13H8, 14F12, and 15G7, in a sterile pharmaceutically acceptable vehicle.

Please add the following claims:

--26. The antibody or epitope-binding fragment thereof of claim 19 that is monoclonal.

C 2

27. The antibody or epitope-binding fragment thereof that is covalently bound to a detectable marker or a water insoluble matrix..

28. The monoclonal antibody or epitope binding fragment thereof of claim 26, selected from the group consisting of monoclonal antibodies 6E10, 13H8, and 6D8.

29. A hybridoma or cell culture comprising an antibody, or epitope-binding fragment thereof, which has the characteristics of a monoclonal antibody selected from the group consisting of 6E10, 13H8, and 6D8 produced by hybridomas with ATCC accession numbers CRL 10514, CRL 10510, and CRL 10513, respectively.

30. A hybridoma of claim 29 selected from the group consisting of hybridoma of ATCC accession numbers CRL 10514, CRL 10510, and CRL 10513.--.

## REMARKS

Claims 19, 20 and 21 have been amended. Support for the amendments are found at page 43, lines 5-15, where the ATCC deposit information is provided as found in the Preliminary Amendment previously submitted, at page 39, line 30 to page 40, line 3, where detectably-labeled monoclonal antibodies and antibodies attached to supports are discussed, and at page 32, lines 3-7, page 36, lines 11-12, and page 37, lines 4-6, where epitope-binding nature of antibodies and antibody